HRP20260016T1 - Modificirani lipidirani peptidi lanca relaksina b i njihova terapijska upotreba - Google Patents

Modificirani lipidirani peptidi lanca relaksina b i njihova terapijska upotreba

Info

Publication number
HRP20260016T1
HRP20260016T1 HRP20260016TT HRP20260016T HRP20260016T1 HR P20260016 T1 HRP20260016 T1 HR P20260016T1 HR P20260016T T HRP20260016T T HR P20260016TT HR P20260016 T HRP20260016 T HR P20260016T HR P20260016 T1 HRP20260016 T1 HR P20260016T1
Authority
HR
Croatia
Prior art keywords
relaxin
chain
therapeutic use
lipidated peptides
modified
Prior art date
Application number
HRP20260016TT
Other languages
English (en)
Croatian (hr)
Inventor
Olivier Duclos
Stéphane ILLIANO
Sergio Mallart
Claire MINOLETTI-HOCHEPIED
Elisabetta Bianchi
Raffaele Ingenito
Paola MAGOTTI
Alessia Santoprete
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20260016T1 publication Critical patent/HRP20260016T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20260016TT 2018-01-31 2019-01-30 Modificirani lipidirani peptidi lanca relaksina b i njihova terapijska upotreba HRP20260016T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use
EP19702593.5A EP3746467B1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (1)

Publication Number Publication Date
HRP20260016T1 true HRP20260016T1 (hr) 2026-02-27

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20260016TT HRP20260016T1 (hr) 2018-01-31 2019-01-30 Modificirani lipidirani peptidi lanca relaksina b i njihova terapijska upotreba

Country Status (29)

Country Link
US (3) US10961295B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746467B1 (cg-RX-API-DMAC7.html)
JP (1) JP7295871B2 (cg-RX-API-DMAC7.html)
KR (1) KR102755938B1 (cg-RX-API-DMAC7.html)
CN (1) CN111770934B (cg-RX-API-DMAC7.html)
AR (1) AR114325A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019214358B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020014834A2 (cg-RX-API-DMAC7.html)
CA (1) CA3089657A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020008308A2 (cg-RX-API-DMAC7.html)
DK (1) DK3746467T3 (cg-RX-API-DMAC7.html)
ES (1) ES3058633T3 (cg-RX-API-DMAC7.html)
FI (1) FI3746467T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260016T1 (cg-RX-API-DMAC7.html)
IL (2) IL276170B2 (cg-RX-API-DMAC7.html)
LT (1) LT3746467T (cg-RX-API-DMAC7.html)
MA (1) MA52994A (cg-RX-API-DMAC7.html)
MX (1) MX2020008096A (cg-RX-API-DMAC7.html)
MY (1) MY199821A (cg-RX-API-DMAC7.html)
NZ (1) NZ766762A (cg-RX-API-DMAC7.html)
PH (1) PH12020551118A1 (cg-RX-API-DMAC7.html)
PL (1) PL3746467T3 (cg-RX-API-DMAC7.html)
PT (1) PT3746467T (cg-RX-API-DMAC7.html)
RS (1) RS67606B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006903WA (cg-RX-API-DMAC7.html)
SI (1) SI3746467T1 (cg-RX-API-DMAC7.html)
TW (1) TWI763972B (cg-RX-API-DMAC7.html)
UY (1) UY38069A (cg-RX-API-DMAC7.html)
WO (1) WO2019149782A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
MY199821A (en) 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2023028008A2 (en) * 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
EP4713001A2 (en) 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288011A1 (en) * 2008-12-05 2011-11-24 Jean-Paul Castaigne Peptide therapeutic conjugates and uses thereof
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素(relaxin)融合多肽類及其用途
AU2012291972B2 (en) * 2011-08-04 2017-03-09 Pharis Biotec Gmbh Process for preparing human relaxin-2
WO2013177529A1 (en) * 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CA2945838C (en) * 2014-04-17 2022-08-16 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
HUE052977T2 (hu) * 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
SG10201912034UA (en) * 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
TW201934572A (zh) * 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素b鏈胜肽及其治療用途
MY199821A (en) 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
WO2023028008A2 (en) * 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Also Published As

Publication number Publication date
PL3746467T3 (pl) 2026-04-13
PT3746467T (pt) 2026-01-13
US20240218042A1 (en) 2024-07-04
CN111770934B (zh) 2024-10-18
US10961295B2 (en) 2021-03-30
AR114325A1 (es) 2020-08-19
AU2019214358A1 (en) 2020-08-20
CA3089657A1 (en) 2019-08-08
JP2021512099A (ja) 2021-05-13
US20190233494A1 (en) 2019-08-01
SI3746467T1 (sl) 2026-02-27
DK3746467T3 (da) 2026-01-12
RU2020126210A (ru) 2022-02-28
CN111770934A (zh) 2020-10-13
IL276170B2 (en) 2025-03-01
US11725036B2 (en) 2023-08-15
SG11202006903WA (en) 2020-08-28
IL276170B1 (en) 2024-11-01
UY38069A (es) 2019-08-30
TWI763972B (zh) 2022-05-11
KR102755938B1 (ko) 2025-01-20
NZ766762A (en) 2026-03-27
FI3746467T3 (fi) 2026-01-16
MA52994A (fr) 2021-05-05
US20210292387A1 (en) 2021-09-23
MX2020008096A (es) 2020-09-24
TW201940505A (zh) 2019-10-16
EP3746467B1 (en) 2025-10-08
RS67606B1 (sr) 2026-01-30
BR112020014834A2 (pt) 2020-12-08
CO2020008308A2 (es) 2020-10-30
MY199821A (en) 2023-11-23
KR20200116085A (ko) 2020-10-08
AU2019214358B2 (en) 2023-05-25
LT3746467T (lt) 2026-01-26
IL316406A (en) 2024-12-01
IL276170A (en) 2020-09-30
ES3058633T3 (en) 2026-03-12
WO2019149782A1 (en) 2019-08-08
EP3746467A1 (en) 2020-12-09
PH12020551118A1 (en) 2021-07-05
JP7295871B2 (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
IL280483A (en) Muscle targeting complexes and uses thereof for treating pompe disease
IL279897A (en) Fusosome compositions and uses thereof
IL276170A (en) Lipid-adapted relaxin B peptide chains and their medical use
DK3784283T3 (da) Cannabidiopræparater og anvendelser deraf
IL272069A (en) Dosage regimens of anti-lag-3 antibodies and uses thereof
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
IL262092A (en) Humanized anti-pacap antibodies and uses thereof
IL280317A (en) Anti-avb8 antibodies and compositions and uses thereof
IL269158A (en) Compositions and methods for treating inflammatory diseases
IL281866A (en) Introducer devices and methods of use thereof
IL269844A (en) Dosing regimens and related compositions and methods
HUE060791T2 (hu) Antigén peptidek rák megelõzésére és kezelésére
IL283942A (en) Tubulysins and protein-tubulysin conjugates
EP3618865A4 (en) HUMAN ANTI-SEMAPHORINE 4D ANTIBODY
PL3600415T3 (pl) Przeciwciało przeciwko receptorowi aktywiny typu II do stosowania w leczeniu niewydolności serca
KR102735988B9 (ko) 치료 항체 제제
HUE058289T2 (hu) Brómdomén és extraterminális protein inhibitor kombinációs terápia
EP3858866A4 (en) GLP1-FC FUSION PROTEIN AND ASSOCIATED CONJUGATE
IL281608A (en) Anti-human cd45rc antibodies and uses thereof
EP3570867A4 (en) THERAPEUTIC PEPTIDES AND NEUROPROTECTORS
EP3476860A4 (en) Recombinant single-chain fviii and chemical conjugate thereof
EP4013440A4 (en) THERAPEUTIC PEPTIDES
DK3512544T3 (da) Peptidforbindelser og terapeutiske anvendelser deraf
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL282157A (en) Compounds and therapeutic uses thereof